Loading clinical trials...
Loading clinical trials...
Immunologic Effects of CpG ODN Administration to HIV Uninfected and HIV Infected Patients
Conditions
Interventions
CpG7909 oligodeoxynucleotides (ODN)
Hepatitis B virus vaccine
Locations
1
United States
University Hospitals of Cleveland
Cleveland, Ohio, United States
Start Date
December 1, 2004
Primary Completion Date
February 1, 2007
Completion Date
October 1, 2007
Last Updated
October 1, 2008
NCT07024641
NCT04142047
NCT06694805
NCT07428330
NCT07225530
NCT06665646
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions